Abstract:
Randomised controlled clinical trial evidence on prophylaxis as optimal care for patients with haemophilia was generated more than a
decade ago. However, this knowledge has not translated into clinical practice in South Africa (SA) owing to many barriers to prophylaxis.
These include the high treatment burden imposed by prophylaxis (frequent injections two to four times a week), the need for intravenous
access to administer replacement clotting factor therapies, and the higher volume of clotting factor required compared with episodic
treatment. The recently introduced non-factor therapies in haemophilia care have addressed many of these barriers. For example,
emicizumab, which is currently the only globally approved non-factor therapy, can be administered subcutaneously less frequently (weekly,
fortnightly or every 4 weeks) and has led to global adoption of prophylaxis as the standard of care in haemophilia by the bleeding disorders
community. Haemophilia A is the most prevalent clotting factor deficiency in SA, with >2 000 people diagnosed to date. However, only
a few of these patients are currently on prophylaxis. In this ‘In Practice’ article, we review the rationale for prophylaxis, outline its goals
and benefits, and provide evidence-based guidance on which haemophilia patients should be prioritised for emicizumab prophylaxis. This
consensus guidance facilitates the adoption of prophylaxis as a national policy and the new standard of care in haemophilia in SA.
